← Back to Search

Virus Therapy

Nanoplexed Poly I:C BO-112 for Liver Cancer

Q: How many individuals are partaking in this experiment?

Affirmative. Clinicaltrials.gov reports that this research trial, initially posted on October 13th 2021, is still vying for applicants. The study requires 15 participants to be enrolled from a single clinical site.

Q: What are the primary medical uses of Nanoplexed Poly I:C BO-112?

Nanoplexed Poly I:C BO-112 is commonly applied to treat malignant neoplasms, unresectable <a href="https://www.withpower.com/clinical-trials/melanoma">melanoma</a>, microsatellite instability high situations and disease progression after chemotherapy.

Q: Can you detail prior experiments using Nanoplexed Poly I:C BO-112?

Presently, Nanoplexed Poly I:C BO-112 has 962 active trials occurring with 122 of them in the final stage. Most are centered around Houston, TX but there are 35,769 clinical trial sites operating studies regarding this compound.

Q: Are investigators currently enrolling participants for this clinical exploration?

Affirmative, the entry posted on clinicaltrials.gov confirms that recruitment is ongoing for this medical study, which was initially publicized in October 2021 and recently revised during November of the same year. 15 volunteers are needed from only one site to complete enrollment.

Phase < 1

Waitlist Available

Led By Richard S Finn

Research Sponsored by Jonsson Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 4 years

Awards & highlights

Study Summary

This trial is testing the side effects and effectiveness of two cancer treatments, BO-112 and pembrolizumab, in patients with liver cancer.

Eligible Conditions

Liver Cancer
Hepatocellular Carcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective response rate (ORR)

Secondary outcome measures

Disease control rate (DCR)

Incidence of adverse events

Overall survival (OS)

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (pembrolizumab, BO-112)Experimental Treatment2 Interventions

Patients receive pembrolizumab IV over 30 minutes on day 1 of odd number cycles. Patients also receive BO-112 by intratumoral injection on day 1, 8, and 15 of cycle 1, and day 15 of subsequent cycles. Treatment repeats every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor

360 Previous Clinical Trials

27,711 Total Patients Enrolled

5 Trials studying Liver Cancer

69 Patients Enrolled for Liver Cancer

Merck Sharp & Dohme LLCIndustry Sponsor

3,892 Previous Clinical Trials

5,061,145 Total Patients Enrolled

2 Trials studying Liver Cancer

133 Patients Enrolled for Liver Cancer

Highlight TherapeuticsIndustry Sponsor

5 Previous Clinical Trials

148 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are partaking in this experiment?

"Affirmative. Clinicaltrials.gov reports that this research trial, initially posted on October 13th 2021, is still vying for applicants. The study requires 15 participants to be enrolled from a single clinical site."

Answered by AI

What are the primary medical uses of Nanoplexed Poly I:C BO-112?

"Nanoplexed Poly I:C BO-112 is commonly applied to treat malignant neoplasms, unresectable melanoma, microsatellite instability high situations and disease progression after chemotherapy."

Answered by AI

Can you detail prior experiments using Nanoplexed Poly I:C BO-112?

"Presently, Nanoplexed Poly I:C BO-112 has 962 active trials occurring with 122 of them in the final stage. Most are centered around Houston, TX but there are 35,769 clinical trial sites operating studies regarding this compound."

Answered by AI

Are investigators currently enrolling participants for this clinical exploration?

"Affirmative, the entry posted on clinicaltrials.gov confirms that recruitment is ongoing for this medical study, which was initially publicized in October 2021 and recently revised during November of the same year. 15 volunteers are needed from only one site to complete enrollment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

2021. "BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04777708.